Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).

被引：0
|
作者：
Lee, Keun-Wook
Klempner, Samuel J.
Yang, Jianning
Desai, Amit
Yamada, Akihiro
Ueno, Yoko
Wojtkowski, Tomasz
Park, Jung Wook
Pavese, Janet
Loupakis, Fotios
Bang, Yung-Jue
Shitara, Kohei
机构：
[1] Seoul Natl Univ, Bundang Hosp, Coll, Seongnam, South Korea
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Astellas Pharma Global Dev, Northbrook, IL USA
[4] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[5] Univ Pisana, Univ Azienda Osped, Pisa, Italy
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16078
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Zolbetuximab + CAPOX in 1L Claudin-18.2+(CLDN18.2+)/HER2-Locally Advanced (LA) Unresectable or Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Primary Phase 3 Results From GLOW
    Lordick, F.
    Xu, R. -H
    Shitara, K.
    Ajani, J. A.
    Bang, Y. -J
    Enzinger, P.
    Ilson, D.
    Van Cutsem, E.
    Gallego Plazas, J.
    Huang, J.
    Shen, L.
    Oh, S. C.
    Sunpaweravong, P.
    Hoo, Soo H. F.
    Turk, H. M.
    Park, J. W.
    Moran, D.
    Bhattacharya, P.
    Arozullah, A.
    Shah, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 116 - 117
  • [12] Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
    Xu, Rui-Hua
    Shitara, Kohei
    Ajani, Jaffer A.
    Bang, Yung-Jue
    Enzinger, Peter C.
    Ilson, David H.
    Lordick, Florian
    Van Cutsem, Eric
    Gallego Plazas, Javier
    Huang, Jing
    Shen, Lin
    Oh, Sang Cheul
    Sunpaweravong, Patrapim
    Soo Hoo, Hwoei Fen
    Turk, Haci M.
    Park, Jung Wook
    Moran, Diarmuid Martin
    Bhattacharya, Pranob P.
    Arozullah, Ahsan
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 405736 - 405736
  • [13] Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER22locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
    Xu, Rui-hua
    Shitara, Kohei
    Ajani, Jaffer A.
    Bang, Yung-Jue
    Enzinger, Peter C.
    Ilson, David H.
    Lordick, Florian
    Van Cutsem, Eric
    Plazas, Javier Gallego
    Huang, Jing
    Shen, Lin
    Oh, Sang Cheul
    Sunpaweravong, Patrapim
    Hoo, Hwoei Fen Soo
    Turk, Haci M.
    Park, Jung Wook
    Moran, Diarmuid Martin
    Bhattacharya, Pranob P.
    Arozullah, Ahsan
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [14] First-line (1L) zolbetuximab plus chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT plus GLOW
    Kang, Y-K.
    Shah, M. A.
    Shitara, K.
    Ajani, J. A.
    Lordick, F.
    Van Cutsem, E.
    Ilson, D. H.
    Klempner, S. J.
    Yamaguchi, K.
    Nakajima, T.
    Cao, Y. J.
    Li, R.
    Moran, D.
    Pophale, R. R.
    Ranganath, R.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S895 - S895
  • [15] Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)
    Shitara, Kohei
    Xu, Rui-Hua
    Moran, Diarmuid Martin
    Guerrero, Abraham
    Li, Ran
    Pavese, Janet
    Matsangou, Maria
    Bhattacharya, Pranob P.
    Ajani, Jaffer A.
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [16] GLOW: Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin18.2./HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Xu, R-H.
    Ajani, J. A.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P. C.
    Ilson, D. H.
    Kim, S.
    Lordick, F.
    Shitara, K.
    van Cutsem, E.
    Arozullah, A.
    Park, J. W.
    Shah, M. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1315 - S1316
  • [17] Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
    Huang, Yufan
    You, Maojin
    Wu, Qundan
    Chen, Ruijia
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [18] A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
    Bang, Y-J
    Kang, Y-K
    Ng, M.
    Chung, H. C.
    Wainberg, Z. A.
    Gendreau, S.
    Chan, W. Y.
    Xu, N.
    Maslyar, D.
    Meng, R.
    Chau, I
    Ajani, J. A.
    EUROPEAN JOURNAL OF CANCER, 2019, 108 : 17 - 24
  • [19] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [20] JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Alsina, Maria
    Weinberg, Zev A.
    Chau, Ian
    Zhu, Jin
    Chan, Wai Y.
    Patel, Premal H.
    Meng, Raymond D.
    Ajanl, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345